Prostanoid receptor signaling relevant to tumor growth and angiogenesis

Trends in Pharmacological Sciences

Volumn 24, Issue 10, 2003, Pages 524-529

  Majima, Masataka ^a   Amano, Hideki ^a   Hayashi, Izumi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR;

ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CANCER; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH;

EID: 0141918838     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.08.005     Document Type: Article

References (61)

1. Smalley W., Dubois R.N. Colorectal cancer and non steroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1997;1-20.
2. Katori M., Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm. Res. 49:2000;367-392.
3. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer. 1:2001;11-21.
4. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:2003;96-102.
5. Chandrasekharan N.V., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13926-13931.
6. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
7. DeWitt D.L. Cox-2-selective inhibitors: the new super aspirins. Mol. Pharmacol. 55:1999;625-631.
8. Okumura T., et al. Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertens. Res. 25:2002;927-938.
9. Norwood V.F., et al. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int. 58:2000;2291-2300.
10. Marx J. Anti-inflammatories inhibit cancer growth-but how? Science. 291:2001;581-582.
11. Prescott S.M., White R.L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell. 87:1996;783-786.
12. Shiff S.J., Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology. 113:1997;1992-1998.
13. Narumiya S., et al. Prostanoid receptors: structures, properties, and function. Physiol. Rev. 79:1999;1193-1226.
14. Yang L., et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111:2003;727-735.
15. Nguyen M., et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature. 390:1997;78-81.
16. Watanabe K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59:1999;5093-5096.
17. 2 in Apc(Delta716) knockout mice. Nat. Med. 7:2001;1048-1051.
18. Seno H., et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62:2002;506-511.
19. Amano H., et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197:2003;221-232.
20. Hanahan D., Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
21. Kitamura T., et al. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 23:2002;1463-1466.
22. Chulada P.C., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60:2000;4705-4708.
23. Dormond O., et al. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. 7:2001;1041-1047.
24. Dormond O., et al. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 277:2002;45838-45846.
25. Tsujii M., et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
26. Ziche M., et al. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69:1982;475-482.
27. Spisni E., et al. Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. Prostaglandins Leukot. Essent. Fatty Acids. 47:1992;111-115.
28. Form D.M., Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172:1983;214-218.
29. Katada J., et al. Significance of vascular endothelial cell growth factor up-regulation mediated via a chymase-angiotensin-dependent pathway during angiogenesis in hamster sponge granulomas. J. Pharmacol. Exp. Ther. 302:2002;949-956.
30. Muramatsu M., et al. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J. Biol. Chem. 275:2000;5545-5552.
31. Hayashi I., et al. Suppressed angiogenesis in kininogen-deficiencies. Lab. Invest. 82:2002;871-880.
32. Majima M., et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br. J. Pharmacol. 130:2000;641-649.
33. Majima M., et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn. J. Pharmacol. 75:1997;105-114.
34. Amano H., et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn. J. Pharmacol. 87:2001;181-188.
35. Murata T., et al. Altered pain perception and inflammatory responses in mice lacking prostacyclin receptor. Nature. 388:1997;678-682.
36. Sugimoto Y., et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science. 277:1997;681-683.
37. Segi E., et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem. Biophys. Res. Commun. 246:1998;7-12.
38. Ushikubi F., et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature. 395:1998;281-284.
39. 2. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10501-10506.
40. 2 as a mediator of allergic asthma. Science. 287:2000;2013-2017.
41. Watanabe K., et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett. 156:2000;57-61.
42. Suzawa T., et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for respective EPs. Endocrinology. 141:2000;1554-1559.
43. Kabashima K., et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109:2002;883-893.
44. Zweifel B.S., et al. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62:2002;6706-6711.
45. Ben-Av P., et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87.
46. Mutoh M., et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 62:2002;28-32.
47. Liu X.H., et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 277:2002;50081-50086.
48. Fukuda R., et al. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63:2003;2330-2334.
49. Smith T.J., et al. Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J. Clin. Endocrinol. Metab. 80:1995;2620-2625.
50. Goldring S.R., et al. Heterogeneity in hormone responses and patterns of collagen synthesis in cloned dermal fibroblasts. J. Clin. Invest. 85:1990;798-803.
51. Ko S.D., et al. Fibroblast heterogeneity and prostaglandin regulation of subpopulations. Proc. Natl. Acad. Sci. U. S. A. 74:1977;3429-3432.
52. Fukumura D., et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151:1997;679-688.
53. Gohongi T., et al. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta. Nat. Med. 5:1999;1203-1208.
54. Sano H., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
55. Williams C.S., et al. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589-1594.
56. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867.
57. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:2002;549-555.
58. De Palma M., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9:2003;789-795.
59. Greenlee R.T., et al. Cancer statistics, 2000. CA Cancer J. Clin. 50:2000;7-33.
60. Sheng H., et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276:2001;18075-18081.
61. Schirner M., Schneider M.R. Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth. Cancer Detect. Prev. 21:1997;44-50.